Terremoto Biosciences

About Terremoto Biosciences

Terremoto Biosciences is pioneering a seismic shift in drug discovery and development by leveraging covalent chemistry, specifically lysine-based covalency, to create superior small molecule medicines with enhanced therapeutic benefits. Their mission is to develop life-changing covalent medicines through innovation, focus, and commitment.

Products & Services

Covalent Medicines:Small molecule drugs developed using a novel lysine-based covalency approach to target a broader universe of drug targets and improve existing medicines.

Specialties

Covalent Chemistry Lysine-based Covalency Drug Discovery and Development Small Molecule Medicines

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2023-11-02 FD: 2023-11-02	5 investors

Series B Latest

2023-11-02

$175.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Charles Baum

Chief Executive Officer

J

James Christensen

President, Head of Research & Development

G

Grace Lu

Chief Business Officer

M

Maika Adair

Director, Clinical Supply Chain, Technical Operations

B

Brian Bestvater

Senior Associate Scientist, Chemistry

N

Noleen Bonfante

Executive Director, Clinical Operations

View 96 more team members with Pro

Unlock Full Team Directory

Recent News